2026-2027呼吸道季节COVID-19疫苗有效性与安全性系统综述
该系统综述检索2025年8月至2026年6月文献,纳入155篇美国许可COVID-19疫苗有效性、 efficacy或安全性及SARS-CoV-2流行病学研究。结果显示更新疫苗与老年人及成人住院风险降低相关,孕产妇接种与婴儿相关就诊减少相关,免疫缺陷成人重症风险降低,未发现新安全信号。
要点
- 更新COVID-19疫苗与≥65岁老年人住院风险降低相关(VE 53.0%,95%CI 37.0%-65.0%)。
- 孕产妇接种与婴儿出生后2个月内COVID-19相关住院接触减少相关(VE范围50.0%-54.0%)。
- 未发现新的安全信号,特殊不良事件谱与既往综述一致。
核心结论
- COVID-19疫苗持续与住院及其他结局风险降低相关,包括婴儿、孕妇等重症高风险人群。
- 未识别出新的安全担忧。
研究设计与样本
- 系统综述检索Cochrane Central Register of Controlled Trials、PubMed/MEDLINE、Embase和Scopus,时间范围为2025年8月1日至2026年6月29日。
主要发现
- 更新COVID-19疫苗与≥65岁老年人住院风险降低相关(VE 53.0%;95%CI 37.0%-65.0%;2025-2026季节)。
- 更新COVID-19疫苗与18-64岁成人住院风险降低相关(VE 54.0%;95%CI 1.0%-78.0%;2024-2025季节)。
- 孕产妇接种与接种者COVID-19相关急诊/紧急护理就诊风险降低相关(VE 58.0%;95%CI 24.0%-77.0%)。
- 孕产妇接种与随后出生婴儿出生后2个月内COVID-19相关住院接触减少相关(VE范围50.0%-54.0%),与接种孕期无关。
- 接种与9个月至4岁儿童COVID-19相关急诊就诊显著减少相关(VE 76.0%;95%CI 58.0%-87.0%)。
关键数值与推荐
- 免疫缺陷成人接种与重症COVID-19(ICU入住或死亡)风险降低相关(VE范围32.0%-53.0%,取决于基础疾病及其他因素)。
- 接种3至5剂疫苗的医护人员较仅接种2剂者实验室确诊COVID-19疾病风险更低(VE 41.0%;95%CI 34.0%-47.0%)。
- 接种3至5剂疫苗的医护人员较仅接种2剂者急性COVID-19后症状风险更低(VE 57.0%;95%CI 46.0%-66.0%)。
- 在扩展基础免疫程序接种间隔新指南下开展的研究未报告心肌炎或心包炎风险增加。
临床怎么用
- 更新COVID-19疫苗可用于降低老年人及成人住院风险。
- 孕产妇接种可能降低自身相关急诊就诊及婴儿早期COVID-19相关住院接触。
- 免疫缺陷成人及医护人员补种疫苗可能降低重症及感染/急性后症状风险。
- 安全性监测未提示新的特殊不良事件信号。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: SARS-CoV-2 remains a substantial cause of respiratory illness, morbidity, and mortality. Evidence to date has demonstrated that COVID-19 vaccines reduce the risk of severe disease, including hospitalization and death. OBJECTIVE: This systematic review identifies and summarizes newly published studies reporting on the effectiveness and safety of COVID-19 vaccines and COVID-19 epidemiology in the US. EVIDENCE REVIEW: Cochrane Central Register of Controlled Trials, PubMed/MEDLINE, Embase, and Scopus were searched from August 1, 2025, through June 29, 2026. Studies were eligible if they reported on the effectiveness, efficacy, or safety of a US-licensed COVID-19 vaccine or SARS-CoV-2 epidemiology in the US. FINDINGS: From 11 829 identified references, 155 publications were eligible (15 randomized clinical trials, 84 observational studies with a comparator group, 38 product safety studies without a comparator group [single group], and 18 descriptive studies of disease burden). Consistent with prior evidence, studies reported that updated COVID-19 vaccines were associated with a reduction in the risk of hospitalization among both older adults (≥65 years; vaccine effectiveness [VE], 53.0%; 95% CI, 37.0%-65.0%; 2025-2026 season) and adults (18-64 years; VE, 54.0%; 95% CI, 1.0%-78.0%; 2024-2025 season). Maternal vaccination was associated with reduced risk of COVID-19-associated emergency department/urgent care encounters among individuals vaccinated (VE, 58.0%; 95% CI, 24.0%-77.0%) and with fewer COVID-19-related hospital contacts in the first 2 months of life among infants born subsequently (VE range, 50.0%-54.0%), regardless of trimester of vaccination. Vaccination was also associated with a significant reduction in COVID-19-related pediatric emergency department visits (9 months to 4 years; VE, 76.0%; 95% CI, 58.0%-87.0%). Vaccination was associated with a reduced risk of critical COVID-19 illness (intensive care unit admission or death) in immunocompromised adults (VE range, 32.0%-53.0%, depending on condition and other factors). Health care personnel who received 3 to 5 vaccine doses were less likely to develop laboratory-confirmed COVID-19 illness (VE, 41.0%; 95% CI, 34.0%-47.0%) and postacute COVID-19 symptoms (VE, 57.0%; 95% CI, 46.0%-66.0%) compared with those who received only 2 doses. Across adverse events of special interest (eg, stroke, thrombosis, myocarditis), safety profiles were consistent with those of previous reviews. No identified studies conducted under the updated guidance on extended dosing intervals for the primary series reported an increased risk of myocarditis or pericarditis. No new safety signals were reported in the recently published studies eligible for this updated review of US-licensed COVID-19 vaccines. CONCLUSIONS AND RELEVANCE: COVID-19 vaccines were consistently associated with a reduction in the risk of hospitalization and other outcomes, including among individuals at high risk of severe COVID-19, such as infants, and those who were pregnant. No new safety concerns were identified.
引用
- Lipson RA, Senerth E, Watson MA, et al. COVID-19 Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season. JAMA. 2026. PMID: 42684258. doi:10.1001/jama.2026.18191
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。